NMS · Biotechnology

AnaptysBio, Inc. (ANAB) Stock

$46.21 +1.23% NMS: ANAB Healthcare

Valuation

MetricValue
Price$46.21
Market Cap$1.37B
P/E Ratio7.19
P/B Ratio134.17
P/S Ratio6.05
EPS (TTM)$-0.46
52-Week High$72.36
52-Week Low$19.65
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE442.91%
ROA61.75%
ROCE47.55%
Gross Margin20.43%
Operating Margin20.43%
Net Margin82.37%
Debt/Equity25.47
Current Ratio8.97

Annual Financials (USD)

Metric20212022202320242025
Revenue$63.0M$10.0M$17.0M$91.0M$235.0M
Operating Profit$-57.0M$-115.0M$-164.0M$-115.0M$48.0M
Net Profit$-58.0M$-129.0M$-164.0M$-145.0M$-13.0M
EPS$-2.11$-4.57$-6.08$-5.12$-0.46
Op Margin-89.9%-1119.4%-958.3%-125.9%20.4%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$643.0M$610.0M$452.0M$484.0M$364.0M
Total Liabilities$287.0M$348.0M$364.0M$413.0M$327.0M
Cash$496.0M$71.0M$36.0M$123.0M$238.0M
Borrowings$21.0M$19.0M$18.0M$369.0M$14.0M

Latest News

What Makes AnaptysBio (ANAB) an Investment Bet? Insider Monkey · Jul 14, 2026 Is AnaptysBio (ANAB) Outperforming Other Medical Stocks This Year? Zacks · May 21, 2026 Wall Street Analysts See a 38.75% Upside in AnaptysBio (ANAB): Can the Stock Really Move This High? Zacks · May 19, 2026 How The Grupo Traxión (BMV:TRAXION A) Story Is Shifting With Cautious New Analyst Targets Simply Wall St. · May 15, 2026 AnaptysBio (ANAB) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now Zacks · May 14, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-46.0M$-74.0M$-121.0M$-135.0M$20.0M
Investing Cash Flow$37.0M$-395.0M$144.0M$95.0M$228.0M
Financing Cash Flow$250.0M$32.0M$-50.0M$-9.0M$-70.0M
Net Cash Flow$245.0M$-424.0M$-35.0M$87.0M$115.0M
Free Cash Flow$-47.0M$-74.0M$-122.0M$-136.0M$20.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA17.18
FCF Yield1.26%
Quick Ratio5.61
Interest Coverage1.61
Return 1Y201.09%
Return 3Y335.51%
Return 5Y206.47%

Ownership

Insiders Held5.68%
Institutions Held101.74%
Institutions Float Held107.86%
Institutional HolderSharesReport Date
EcoR1 Capital, LLC7,880,0942026-03-31
Blackrock Inc.1,681,3802026-03-31
Tang Capital Management, LLC1,330,8792026-03-31
Morgan Stanley993,9052026-03-31
State Street Corporation992,4452026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $340.42 +1.11% 38.93 $5.00T 0.32%
MSFTMicrosoft Corporation $522.61 -1.35% 28.68 $3.88T 0.76%
GOOGLAlphabet Inc. $348.29 -0.63% 16.94 $4.22T 0.26%
AMZNAmazon.com, Inc. $254.06 -2.25% 19.82 $2.73T 0.00%
METAMeta Platforms, Inc. $720.89 -0.06% 27.93 $1.84T 0.28%

About AnaptysBio, Inc.

AnaptysBio, Inc. (ANAB) stock trades at $46.21 with a market capitalization of $1.37B. The stock is valued at a price-to-earnings (P/E) ratio of 7.19, price-to-book of 134.17, price-to-sales of 6.05. Over the past 52 weeks the stock has ranged between $19.65 and $72.36, and currently trades 36.1% below its 52-week high.

On profitability, AnaptysBio, Inc. generates a return on equity (ROE) of 442.91% — well above the market average, a sign of a high-quality business, return on capital employed of 47.55%, an operating margin of 20.43%, a net profit margin of 82.37%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1169.93 -1.58% JNJ Johnson & Johnson $256.48 -0.76% ABBV AbbVie Inc. $272.42 +0.39% MRK Merck & Company, Inc. Common Stock (new) $142.40 -0.28% UNH UnitedHealth Group Incorporated Common Stock (DE) $370.95 -1.34% NVS Novartis AG $143.11 -0.12% AZN AstraZeneca PLC $158.78 -0.84% TMO Thermo Fisher Scientific Inc $651.98 -1.52% AMGN Amgen Inc. $407.44 -1.37% GILD Gilead Sciences, Inc. $147.10 +0.17% ABT Abbott Laboratories $98.49 -0.24% NVO Novo Nordisk A/S $38.18 -0.21%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides